Crude-led risk-off keeps Nifty pinned below 24,450
Gift Nifty at 24,513.5, Brent at $89.16 and WTI at $83.49 kept the tone heavy. Nifty spot stayed below 24,450 while options positioning cooled from a 0.7717 PCR to 0.6931.
Why the tape looks like this
Biotechnology leads (+2.67%), Glass - Industrial lags
14 of 14 sector groups are positive — breadth backs the move.
Options pin the tape at 24,450
PCR 0.69 (call-writer edge), spot 24,439.60. PCR has moved 0.77 → 0.69 since the open.
Why Is Share Market Falling Today? Know Key Reasons Behind Sensex, Nifty Decline on August 11 | Markets News
Top-ranked story this edition · News18.
Options Board
Shift since openPCR
0.77 → 0.69
call-writer edge
Max Pain
24,450
Spot
24,439.60
Open interest by strike
as of 12:40 ISTKey Developments
Since the openWhy Is Share Market Falling Today? Know Key Reasons Behind Sensex, Nifty Decline on August 11 | Markets News
Stock Market LIVE: Sensex near day's low, down 400 pts; Nifty around 24,550; ZEEL shares drop 5%
Sensex today | Stock Market Live: Noon trade - Sensex falls over 450 points as elevated crude oil prices weigh on equities
Why it matters — Sensex, Nifty, Share Prices Live: Indian equities opened lower on Tuesday as elevated crude prices and Strait of Hormuz
Sensex at risk of slipping below 78,000 as rising crude prices rattle Indian markets
Triveni Turbine shares tumble 8% after Q1 profit drops 20%, margins shrink
Why it matters — Triveni Turbine has reported a net profit of ₹51.1 crore in Q1FY27, down 20 per cent from ₹64.4 crore posted in the year
Triveni Turbine Share Price Falls 5% After Q1 Net Profit Declines 22%
Why it matters — Triveni Turbine reported a 22% decline in Q1 net profit to Rs 51 crore despite 19% revenue growth to Rs 443 crore
Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?
Why it matters — Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profi
Still to Come
Results · macro · corporate actionsMacro & corporate actions
13
Educational market commentary only. Not SEBI-registered investment advice.